Latest Breakthroughs in Cancer Treatment 2025: What You Need to Know

Despite trillions spent on cancer research, cancer still kills around 10 million people a year and is a leading cause of death globally, according to the World Health Organization. Cancer research continues to advance at an unprecedented pace, with new treatments offering hope to millions of patients worldwide.

 

Credit: Statista

Breast, lung and colon cancer are among the most common, while the number of new cancer cases annually is expected to grow by more than 75% between 2022 and 2050.

As we enter 2025, several groundbreaking therapies and innovations—including personalized vaccines, gene-editing technologies, repurposed drugs, and alternative cancer treatments—are reshaping cancer care.

Here are some of the most promising breakthroughs to watch for this year:

1. Next-Generation Immunotherapy

Advances in immunotherapy continue to improve survival rates. Novel checkpoint inhibitors, CAR-T cell therapies, and bispecific antibodies are expanding treatment options for hard-to-treat cancers like pancreatic and brain tumors.

Using immunotherapy as a Neo-adjuvant Strategy (before surgery or other treatments) is gaining traction, with evidence that checkpoint inhibitors alone may be sufficient in some cases, potentially changing standard care protocols (AACR 2025).

Intra-tumoral immunotherapy represents a promising strategy to convert tumors into in situ vaccines, offering targeted immune activation with reduced toxicity. While clinical success has been observed in accessible tumors like melanoma, challenges persist in achieving consistent systemic responses and treating visceral metastases. Future advancements in delivery techniques and combination therapies hold significant potential to broaden its applicability.

Related: 

• Combining Repurposed Drugs with Immunotherapy: A Novel Approach to Cancer Treatment
• Immunotherapy 101: What You Need to Know 2025 (Part 1)
• Approaches to Overcome the Current Treatment Plateau in Immunotherapy (European Journal of Cancer 2025)

CAR-T-cell therapy

A treatment that makes immune cells hunt down and kill cancer cells was declared a success for leukaemia patients in 2022. Known as CAR-T-cell therapy, it involves removing and genetically altering immune cells, called T cells, from cancer patients. The altered cells then produce proteins called chimeric antigen receptors (CARs), which can recognize and destroy cancer cells. In the journal Nature, scientists at the University of Pennsylvania announced that two of the first people treated with CAR-T-cell therapy were still in remission 12 years on.

More recently, the same journal announced that a woman treated with CAR-T therapy as a four-year-old is in remission 19 years later.

However, the US Food and Drug Administration is currently investigating whether the process can in fact cause cancer, after more than 30 cases of secondary cancer were observed in patients receiving CAR-T therapies. The jury is still out as to whether the therapy is to blame but, as a precaution, the drug packaging now carries a warning.

Related: CAR T-Cell Therapy for Glioblastoma: 3 Case Reports

2. AI-Driven Drug Discovery

Artificial intelligence is revolutionizing drug discovery by identifying new cancer-fighting compounds at an accelerated rate. AI algorithms analyze vast datasets to pinpoint potential treatments, significantly reducing the time required for drug development.

3. CRISPR Gene Editing in Cancer Therapy

CRISPR technology has progressed to clinical trials, allowing scientists to edit genes within cancer cells or immune cells to enhance treatment. This approach aims to correct genetic mutations responsible for tumor growth and improve immune system targeting.

4. Personalized Cancer Vaccines

Cancer vaccines have evolved beyond prevention, with new personalized vaccines targeting individual tumors. These mRNA-based therapies train the immune system to recognize and attack cancer cells, offering a promising avenue for highly tailored treatments. 

Thousands of NHS cancer patients in England could soon access trials of a new vaccine treatment. It's designed to prime the immune system to target cancer cells and reduce recurrence risk. These vaccines are also hoped to produce fewer side effects than conventional chemotherapy. Thirty hospitals have joined the Cancer Vaccine Launch Pad, which matches patients with upcoming trials using the same mRNA technology found in current COVID-19 jabs. Over 200 patients from the UK, Germany, Belgium, Spain and Sweden will receive up to 15 doses of the personalized vaccine, with the study expected to complete by 2027.

Repurposed drugs like metformin are being explored as part of alternative cancer treatment strategies to enhance immune responses by altering cancer cell metabolism, potentially boosting vaccine efficacy in combination therapies [PubMed 2021].

5. AI-based Risk Profiling

In India, World Economic Forum partners are using emerging technologies like artificial intelligence (AI) and machine learning to transform cancer care. For example, AI-based risk profiling can help screen for common cancers like breast cancer, leading to early diagnosis. AI technology can also be used to analyze X-rays to identify cancers in places where imaging experts might not be available. These are two of 18 cancer interventions that the Centre for the Fourth Industrial Revolution India, a collaboration with the Forum, hopes to accelerate.

Credit: Science/Cambridge University Hospitals

6. Repurposed Drugs: Unlocking New Potential in Alternative Cancer Treatment

Old meets new. A significant breakthrough in 2025 is the growing and trending use of repurposed drugs as alternative cancer treatments—medications originally developed for non-cancer conditions but now showing promise in oncology. 

Repurposing drugs as a market development strategy is a well-established and highly effective approach within the pharmaceutical industry. Rather than developing entirely new compounds from scratch—a process that can be costly, time-consuming, and fraught with uncertainty—companies identify new therapeutic uses for existing drugs. This strategy not only accelerates the development timeline but also leverages existing safety and efficacy data, reducing regulatory risks.

Many blockbuster drugs owe their commercial and clinical success to this approach. For example, Viagra was initially developed to treat hypertension and angina but found enormous success as a treatment for erectile dysfunction. Keytruda, originally designed for melanoma, has since been approved for a wide range of cancers, including lung, bladder, and head and neck cancers, significantly expanding its market potential. Similarly, Ozempic was first developed for type 2 diabetes management but has gained attention for its effectiveness in weight management, tapping into a new patient population.

Drugs like ivermectin, mebendazole, and fenbendazole, traditionally used as antiparasitic agents, are being studied for their anticancer properties. A peer-reviewed protocol published in September 2024, led by researchers such as Dr. Ilyes Baghli and Dr. Paul Marik, demonstrates that these drugs can disrupt cancer cell growth by targeting microtubules, essential for cell division [Baghli et al 2024].

A significant breakthrough in 2025 is the growing use of repurposed drugs—medications originally developed for non-cancer conditions but now showing promise in oncology. Drugs like ivermectin, mebendazole, and fenbendazole, traditionally used as antiparasitic agents, are being studied for their anticancer properties. A peer-reviewed protocol published in September 2024, led by researchers such as Dr. Ilyes Baghli and Dr. Paul Marik, demonstrates that these drugs can disrupt cancer cell growth by targeting microtubules, essential structures for cell division. When used in combination, they exhibit a synergistic effect, offering a potent, affordable treatment option [Baghli et al 2024].

Additionally, drugs like metformin, originally developed for diabetes, and anastrozole, a breast cancer treatment now repurposed for prevention, are gaining traction. Metformin disrupts cancer cell metabolism, while anastrozole reduces estrogen levels to lower breast cancer risk. These repurposed drugs are particularly valuable in low- and middle-income countries, where access to expensive therapies is limited, and their established safety profiles accelerate their integration into clinical practice.

While anecdotal reports, such as more than 150 case studies on fenbendazole, suggest benefits, controlled clinical trials are needed to confirm efficacy. Patients considering these treatments should consult integrative oncologists to tailor protocols to their needs.

7. Tumor Microenvironment Targeting

Researchers are focusing on modifying the tumor microenvironment to make cancer cells more vulnerable to treatment. New drugs are being designed to alter the surrounding cells, cutting off the tumor’s support system.

8. Liquid Biopsies for Early Detection

Liquid biopsies—blood tests that detect cancer-related genetic mutations—are becoming more refined and accessible. These non-invasive tests allow for early cancer detection, real-time monitoring, and personalized treatment adjustments.

9. Gut Microbiome and Cancer Therapy

The gut microbiome’s role in cancer treatment is gaining attention, with research showing that certain gut bacteria can enhance the effectiveness of immunotherapy. Personalized probiotics and microbiome-targeted therapies are under investigation.

10. AI-Assisted Radiotherapy

Radiotherapy is becoming more precise with AI-powered systems that tailor radiation doses to individual patients. This reduces damage to healthy tissues and improves overall treatment outcomes.

11. Holistic Approaches and Integrative Medicine

Complementary therapies such as dietary interventions are being integrated into traditional cancer care as part of alternative cancer treatment approaches to improve patient well-being and enhance treatment efficacy. 

Repurposed drugs like ivermectin are increasingly incorporated into holistic protocols, with case reports suggesting benefits for aggressive cancers when combined with dietary and lifestyle changes [Baghli et al 2024].

12. Fighting pancreatic cancer

Pancreatic cancer is one of the deadliest cancers. It is rarely diagnosed before it starts to spread and has a survival rate of less than 5% over five years. At the University of California San Diego School of Medicine, scientists developed a test that identified 95% of early pancreatic cancers in a study. The research, published in Nature Communications Medicine, explains how biomarkers in extracellular vesicles – particles that regulate communication between cells – were used to detect pancreatic, ovarian and bladder cancer at stages I and II. And now a new test, coined PAC-MANN, can pick up signs of the disease from just one drop of blood, say researchers.

Scientists are also getting closer to a cure. A US/UK study has discovered that pancreatic cancer shuts down particular molecules in a key gene. The hope now is that the new knowledge "could lead to the development of more effective treatment options in the future”, Dr Chris Macdonald, head of research at Pancreatic Cancer UK, told The Guardian.

Related: Potential Role of Fenbendazole and Ivermectin in the Treatment of Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights.

13. Precision Medicine and Genomics

Precision medicine, powered by advances in genomics, is revolutionizing how cancer is diagnosed, treated, and even prevented. Unlike the traditional “one-size-fits-all” approach, precision medicine tailors prevention and treatment strategies to each person’s unique genetic makeup, environment, and lifestyle. This shift is leading to more effective therapies, fewer side effects, and earlier interventions (1, 2, 3). Read More: How Precision Medicine & Genomics Are Transforming Cancer Care and Prevention.

Final Thoughts

The landscape of cancer treatment in 2025 is marked by rapid innovation, from high-tech solutions like CRISPR and AI to practical, cost-effective alternative cancer treatments like repurposed drugs and holistic integrative approaches.

These advancements bring new hope for patients and medical professionals, particularly in making advanced care more accessible globally. While many of these breakthroughs are still in early stages, their potential to revolutionize cancer care is undeniable. Staying informed about the latest advancements, including the promise of repurposed drugs, can help patients and caregivers make more informed treatment decisions.

Related: 

Top 10 Pharmaceutical Companies by Revenue

Top 10 most anticipated drug launches of 2025

Top 10 Pharma Companies by Market Cap (2025)